ACT in the OR vs. ICU: Unraveling the Mystery of Anticoagulation Monitoring in ECMO

With 18 months of experience as an ECMO specialist, I’ve observed an interesting contrast in how anticoagulation is monitored in the operating room (OR) versus the intensive care unit (ICU). This difference has always intrigued me, especially regarding Activated Clotting Time (ACT). ACT is the dominant method in the OR, while it plays a more limited role in the ICU. Today, I’d like to explore why ACT is the preferred tool in the OR but takes a back seat during long-term ECMO management in the ICU.

The OR’s Golden Standard: ACT

In the high-pressure environment of the OR, particularly during ECMO initiation or cardiac surgery, ACT is the test of choice for monitoring anticoagulation. But why is this so?

• Real-time Results: ACT provides results within minutes, making it invaluable in the OR, where immediate decisions and adjustments are often necessary.

• A Broad Measure of Coagulation: ACT offers a global perspective on clotting status, which is essential during surgeries when multiple factors—such as heparin dosage, platelet count, and temperature—can influence coagulation.

• Immediate Feedback for Heparinization: High doses of heparin are administered when ECMO is initiated or during other critical transitions. ACT allows for quick, real-time adjustments to ensure the patient is adequately anticoagulated without overdoing it.

The ICU Perspective: Why ACT Takes a Back Seat

The focus shifts to different tests in the ICU, particularly during long-term ECMO support. While ACT provides immediate feedback, ICU settings allow for more comprehensive, nuanced monitoring. Here’s why aPTT (Activated Partial Thromboplastin Time) and anti-Xa levels are often preferred:

• Precision Over Speed: Unlike the fast-paced OR, ICU environments provide more time for measured, detailed anticoagulation management. Tests like aPTT and anti-Xa deliver precise insights needed to tailor anticoagulation therapies over time.

• Complex Patient Profiles: ICU patients often have underlying conditions that affect their clotting profiles, such as liver dysfunction, sepsis, or multi-organ failure. These conditions necessitate a more nuanced and tailored approach to anticoagulation monitoring.

• Multimodal Approach: Long-term ECMO support often requires a combination of anticoagulation tests to capture the patient’s evolving coagulation status fully. Relying solely on ACT wouldn’t provide the detailed information needed to manage these complex cases.

Image created using DALL·E 3 and MS Designer

When ACT Resurfaces in the ICU

Though ACT isn’t the primary test in the ICU, it does have a role in certain high-stakes scenarios:

• ECMO “Turn Downs”: When reducing ECMO support, large doses of heparin are often administered to prevent clotting as blood flow decreases. In these situations, ACT monitors the immediate anticoagulation effect and ensures safety.

• Weaning Patients off ECMO: When transitioning patients off ECMO support, ACT can monitor rapid changes in coagulation status, allowing for quick adjustments as the patient is weaned from the circuit.

Key Takeaways for Healthcare Professionals

1. Context is Crucial: The choice between ACT and other anticoagulation monitoring methods should always be guided by the clinical context and the patient’s specific needs.

2. Complementary Approaches: In complex cases, combining ACT, aPTT, and anti-Xa levels can provide the most comprehensive picture of a patient’s coagulation status.

3. Continuous Learning: As understanding anticoagulation management in ECMO evolves, staying informed about the latest practices is essential for delivering the best patient care.

By recognizing these nuances, we can better tailor anticoagulation management across different clinical settings, ensuring our patients receive the safest and most effective care possible.

Repost and Subscribe. Join the ECMO 143 Learning Journey:

Enjoy this? Please share this article with others and subscribe to my free newsletter.

Note: This article reflects my learning journey in ECMO and is intended for educational purposes only. It should not be used as a substitute for professional medical advice or guidance. Always consult with qualified healthcare professionals for clinical decisions and patient care.

Other Links:

Follow me on LinkedIn: Jonathan B. Jung, RRT-NPS

• Stay updated on X (Twitter): Follow the “ECMO 143 - Stay Up to Date” List

• Check out my Week in Review Podcast on YouTube: ECMO 143

• Join the discussion on Facebook: ECMO 143 Facebook Group

Acknowledgments:

I developed three custom GPTs, “AI ECMO Expert,” “ECMO Specialist Handover Practice,” and “Micro Definitions (MD-GPT),” for specialized research. These tools draw primarily from the ELSO Redbook (6th Edition), the ELSO Specialist Training Manual (4th Edition), various research papers, and articles. Additional research was supported by GPT-4o/o1, Claude 3.5 Sonnet/Opus, and Perplexity. Editing was performed with Grammarly. A.I. images and charts were created using Leonardo AI, DALL-E3 AI Image Generator, Microsoft Designer, and Adobe Express. Content for all articles sourced from Extracorporeal Life Support: The ELSO Red Book, 6th Edition, and ECMO Specialist Training Manual, 4th Edition.